In this webinar, Dr. Marlise Luskin from Dana Farber Cancer Institute will define high-risk MDS versus low-risk MDS, impact for patients and what treatment options are available.
This webinar is brought to you by the generous support of Celgene, Takeda and Jazz Pharmaceuticals.
Негізгі бет Low Risk vs High Risk MDS - What's the Difference?
Пікірлер: 8